Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2010-11-01
2011-10-25
Saeed, Kamal (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
08044089
ABSTRACT:
Compositions and methods for inhibiting translation using 3-(5-tert-Butyl-2-Hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one and/or its derivatives are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using 3-(5-tert-butyl-2-hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one and/or its derivatives are described.
REFERENCES:
patent: 4053483 (1977-10-01), Hosta Pujol et al.
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 5849780 (1998-12-01), Di Malta et al.
patent: 5914431 (1999-06-01), Fennhoff
patent: 2007/0299102 (2007-12-01), Felding et al.
patent: 2521966 (1975-11-01), None
patent: 19638888 (1998-03-01), None
patent: 10202874 (2003-08-01), None
patent: 200400576 (2004-04-01), None
patent: 200400693 (2004-05-01), None
patent: 2004701153 (2004-07-01), None
patent: 200401216 (2004-08-01), None
patent: 50-154242 (1975-12-01), None
patent: 7301916 (1995-11-01), None
patent: 8183853 (1996-07-01), None
patent: 2002179649 (2002-06-01), None
patent: 2002179650 (2002-06-01), None
patent: 2003176269 (2003-06-01), None
patent: 1823440 (1996-11-01), None
patent: 03078394 (2003-09-01), None
patent: 2005097107 (2005-10-01), None
patent: 2006083869 (2006-08-01), None
patent: 2006083970 (2006-08-01), None
patent: 2008071387 (2008-06-01), None
patent: 2008129075 (2008-10-01), None
English Translation of Rejection Notice relating to corresponding JP Application No. 2006-553263, 2010.
English Abstract of JP Application No. 50-154242, 1975.
Barker, M., et al., “Oxindoles from α-Acyloxyamides,” J. Heterocyclic Chem., 14, 521 (1977).
Ogata, M., et al., “Synthesis and Antimycotic Properties of 3-(1-Imidazolyl)Indolin-2-Ones,” Eur. J. Med. Chem.—Therapeutica, Jul.-Aug. 1981-6, No. 4, pp. 373-379.
English Abstract of JP2002179649; Jun. 26, 2002; Tsujigami, et al.
English Abstract of JP2002179650; Jun. 26, 2002; Tsujigami, et al.
English Abstract of JP2003176269; Jun. 24, 2003; Ashimori, et al.
Watkins, et al., Translation Initiation and Its Deregulation During Tumorigenesis, journal, Feb. 8, 2002, 1023-1027, 86 (7), Bristish Journal of Cancer, UK.
Wang, et al., Expression of the Eukaryotic Translation Initiation Factors 4E and 2a Correlates with the Progression of Thyroid Carcinoma, abstract and presentation platform; Mar. 1999, 1101-1107, vol. 11, No. 12, MaryAnn Liebert, Inc., San Francisco.
Wang, et al., Expression of Eukaryotic Translation Initiation Factors 4e and 2a in Non-Hodgkin's Lymphomas, journal, Jul. 1999, 247-255, vol. 155 No. 1, American Journal of Pathology, US.
Rosenwald, The Role of Translation in Neoplastic Transformation From a Pathologist's Point of View, journal, 2004, 3230-3247, Nature Publishing Group, Albuquerque, NM.
Rosenwald, et al., Expression of Translation Initiation Factor elF-2a is Increased in Benign and Malignant Melancitytic and Colonic Epithelial Neoplasms, journal, Sep. 1, 2003, 1080-1088, vol. 98. No. 5, American Cancer Society.
Meric, et al., Translation Initiation in Cancer: A Novel Target for Therapy, journal, Sep. 2002, 971-979, vol. 1, Houston, TX.
Marintchen, et al., Topology and Regulation of the Human EIF4A/4G/4H Helicase Complex in Translation Initiation, Feb. 6, 2009, 1-14, Elsevier, Inc.
Natarajan, et al., Journal of Medicinal Chemistry, journal, Oct. 7, 2004, 4978-4981, vol. 47 No. 21, American Chemical Society, Cambridge, MA.
Bilanges, et al., Mechanisms of Translation Deregulation in Human Tumors and Therapeutic Intervention Strategies, journal, Apr. 2, 2007, 5973-5990, USF Cancer Research, San Fransico, CA.
International Preliminary Report on Patentability relating to PCT/US2005/004373, filed Feb. 11, 2005.
Shoichet et al., Structure-Based Discovery of Inhibitors of Thymidylate Synthase, Mar. 5, 1993, Science, vol. 259, 1445-1450.
Lala, et al., Cancer and Metastasis reviews (1998), 17 (1), 91-106.
Aktas, et al., “Depletion of Intracellular Ca2+Stores, Phosphorylation of elF2alpha, and sustained inhibitionof translation initiation mediate the anticancer effects of clotrimazole,” Proc. Natl. Acad. Sci. USA 195: 8280-8285 (1998).
Benzaquen, et al., “Clotrimazole inhibits cell proliferation in vitro and in vivo,” Nature Medicine, 1:534-540 (1995).
Bodanszky, et al., “formation of the Peptide Bond,” Peptide Synthesis, Chapter 5, pp. 85-128. John Wiley & Sons. New York (1976).
Hewawasam, et al., “The Synthesis and Characterization of BMS-204352 (MaxiPost™) and Related 3-Flourooxindoles as Openers of Maxi-K Potassium Channels.” Bioorganic & Medicinal Chemistry Letters, 12:1023-1026 (2002).
Klumpp et al., “Preparation of 3, 3-Diaryloxindoles by Superacid-Induced Condsations of Isatins and Anomatics with a Combinatorial Approach,” J. Org. Chem., 63:4481-4484 (1998).
Kozak J., “An Analysis of Vertebrate mRNA Sequences: Intimations of Translational Control,” Cell. Biol., 115:887-903 (1991).
Kozak, “Initiation of Translation in Prokaryotes and Eukaryotes,” Gene, 234:187-208 (1999).
Kozak, “Deteminants of Translational Fidelity and Efficiency in Vertebrate mRNAs,” Biochimie, 76:815-821 (1994).
Miyawaki, et al., “Cameleons as Cytosolie and Intra-Organellar Calcium Probes,” Oxford University Press:Oxford, London;pp. 3-16 (2001).
Pain, “Initiation of Protein Synthesis in Eukaryotic Cells,” Eur. J. Biochem., 236-747-771 (1996).
Palakurthi, et al., “Inhibition of Translation Initiation Mediates the Anticancer Effect of the n-3 Polyunsaturated Fatty Acid Eicosapentaenoic Acid,” Cancer Research, 60:2919-2925 (2000).
Palakurthi, et al., “Anticancer Effects of Thiazolidinediones Are Independent of Peroxisome Prolferator-Activated Receptor γ . . . ,” Cancer Research, 61: 6213-6218 (2001).
Stewart and Young, Solid Phase Peptide Synthesis, pp. 31-34 and 71-82, Pierce Chemical Company, Rockford, IL 1984.
Moerke, et al., “Small-Molecule Inhibition of the Interaction between the Translation Initiation Factors eIF4E and eIF4G,” Cell, vol. 28, pp. 257-267 (2007).
Golub, et al., “Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring,” Science, 286: 531-537 (1999).
Supplementary Partial European Search Report Corresponding to EP 05722960.1 filed Aug. 11, 2006.
Chemical Abstract of Bolotov, V.V., et al., “Synthesis and Antiinflammatory Activity of 3,3-diphenyl-2-oxoindolecarboxylic Acids and Their Amides,” XP002540991, 1980.
Chemical Abstract of Petyunin, P.A., et al., “Chemistry of Heterocycles.XXXI. Synthesis of 3,3-di-aryloxindoles and 1-methyl-3-oxo-4, 4-Diphenyltetra hydroisoquinoline Based on Arylamides of Diphenylchloroacetic and Diphenylakoxyacetic Acids,” XP002540992, 1957.
Chemical Abstract of Shklyaev, V.S., et al., “Reactivity of Compounds with a Diarylmethylol Group XVIII. Cyclization Kinetics of Substituted Anilides of di-p-tolylglycolic and Benzilic Acids” XP002540993, 1972.
Chemical Abstract of Barker, Marvin W, et al., “Oxindoles From. alpha.-acyloxyamides” XP002540994, 1977.
Chemical Abstract of Petyunin, P.A., et al., “Chemistry of Heterocycles. LIII Case of Deamination During the Acidochromic Cyclization if Arylamides of Diarylglycolic Acids,” XP00254995, 1972.
Chemical Abstract of Petyunin, P.A., et al., “Chemistry of Heterocycles. L. Aminoalkylation or 3,3-disubstituted Oxindoles” XP00254996, 1973.
Chemical Abstract of Bolotov, V.V., et al., “Synthesis and Anti-inflammatory Activity of 3, 3-disubstituted 2-oxoindoline-1-acetic Acids and Their Derivatives,” XP002540997, 1979.
Chemical Abstract of Ogata, Masaru, et al., “Synthesis and Antimycotic Properties of 3-(1-imidazolyl) indolin-2-ones,” XP002540998, 1981.
Natarajan, Amarnath, et al., “3, 3-Diaryl-1, 3-dihydroindo
Aktas Huseyin
Chen Han
Fan Yun-Hua
Halperin José A.
Natarajan Amarnath
Banner & Witcoff , Ltd.
Bianchi Kristin
President and Fellows of Harvard College
Saeed Kamal
LandOfFree
3-3-di-substituted-oxindoles as inhibitors of translation... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-3-di-substituted-oxindoles as inhibitors of translation..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-3-di-substituted-oxindoles as inhibitors of translation... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4285630